Life-Saving Immunity with Conjugate Vaccines

Introduction

The fight against meningococcal and pneumococcal infections is critical in safeguarding global public health. These infections can lead to severe illnesses such as meningitis, sepsis, and pneumonia, all of which carry high morbidity and mortality rates if left untreated. Our patented conjugate vaccine offers a powerful defense, providing broad-spectrum immunity that targets both meningococcal and pneumococcal infections with superior efficacy. This innovation promises to change the landscape of vaccine development, offering a tool that can save countless lives around the world.

The Need for Advanced Vaccines

Meningococcal and pneumococcal diseases are leading causes of severe health issues in both children and adults. While current vaccines offer protection, they often come with limitations, such as inadequate coverage against certain strains or suboptimal immune responses in vulnerable populations. These diseases continue to pose significant challenges, particularly in regions with limited access to effective healthcare.

There is an urgent need for vaccines that not only offer broader protection but also enhance the immune response across all demographics. A robust vaccine should provide long-lasting immunity and be capable of addressing multiple strains of these dangerous bacteria.

Why Choose Conjugate Vaccines for Disease Prevention?

Our conjugate vaccine technology addresses these critical needs by combining components of both meningococcal and pneumococcal bacteria into a single, powerful immunization. This vaccine triggers a strong immune response that not only covers multiple strains but also ensures lasting protection. The conjugate design enhances the body’s ability to recognize and fight off these bacteria, reducing the risk of severe illness, hospitalization, and death.

This vaccine is also ideal for distribution in regions with high disease burdens, where access to healthcare may be limited. By offering broader protection, fewer doses may be required, simplifying vaccination schedules and making it easier to reach vulnerable populations.

Key Benefits

Broad-Spectrum Immunity: Targets multiple strains of meningococcal and pneumococcal bacteria.
Enhanced Immune Response: Provides long-lasting protection across various age groups.
Efficient Distribution: Ideal for global health initiatives, with fewer doses required.
Life-Saving Potential: Reduces the incidence of severe illness and death from these infections.

Save Lives with Conjugate Vaccines for Disease Prevention

Licensing this innovative vaccine technology equips pharmaceutical companies and public health organizations with a life-saving tool. Offering enhanced protection and simplified distribution, this vaccine is poised to make a significant impact on global health.

Please see terms and conditions

Abstract
Claims

This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both S. pneumoniae and N. meningitides in a subject. In a preferred aspect, the immunogenic composition comprises covalently conjugated recombinant PsaA (“rPsaA”) from S. pneumoniae and capsular polysaccharide from N. meningitidis serogroup C. This disclosure further relates to methods for producing the immunogenic composition as well as methods for their use.

1. An immunogenic composition comprising isolated capsular polysaccharide from serogroup C Neisseria meningitidis, wherein the capsular polysaccharide is conjugated to purified pneumococcal surface antigen A (PsaA), the PsaA being 309 amino acid residues in length, wherein the immunogenic composition generates a murine serum IgG response to both the serogroup C Neisseria meningitidis and the PsaA when administered to mice in an immunogenically effective amount, the murine serum IgG response generated to the serogroup C Neisseria meningitidis and the PsaA being greater than murine serum IgG immune response generated by each of the serogroup C Neisseria meningitidis and the PsaA in a non-conjugated form.

2. An immunogenic composition comprising isolated capsular polysaccharide from serogroup C Neisseria meningitidis, wherein the capsular polysaccharide is conjugated to purified pneumococcal surface antigen A (PsaA), the PsaA being a recombinant PsaA that comprises at least amino acid residues 21 to 319 of SEQ ID NO: 1, wherein the immunogenic composition generates a murine serum IgG response to both the serogroup C Neisseria meningitidis and the PsaA when administered to mice in an immunogenically effective amount, the murine serum IgG immune response generated to the serogroup C Neisseria meningitidis and the PsaA being greater than murine serum IgG immune response generated by each of the serogroup C Neisseria meningitidis and the PsaA in a non-conjugated form.

3. The immunogenic composition of claim 1 or 2 further comprising one or more pharmaceutically acceptable diluents, carriers, adjuvants, and/or buffers.

4. The immunogenic composition of claim 2, wherein the immunogenic composition elicits a bactericidal immune response in said mice against serogroup C Neisseria meningitidis.

5. A method comprising administering to a subject an amount of the immunogenic composition of claim 1, 2 or 3.

Title

Meningococcal and pneumococcal conjugate vaccine and method of using same

Inventor(s)

Stanley Shih-Peng Tai, Che-Hung Robert Lee

Assignee(s)

Howard University, National Institutes of Health NIH

Patent #

8003112

Patent Date

August 23, 2011